Novo Nordisk: Mr. Market Pricing In Success, But It's Too Early To Bank On That (NYSE:NVO)
· seekingalpha.com
Novo Nordisk rated a hold as Ozempic/Rybelsus weakness hits revenue despite strong cash flow and cheap valuation. Click for more on NVO stock.
Crude Value Insights offers you an investing service and community focused on oil and natural gas. We focus on cash flow and the companies that generate it, lea...